MINIMUM SALES OBLIGATIONS Sample Clauses

MINIMUM SALES OBLIGATIONS. CREATIVE agrees to purchase the following cumulative minimum copies: (i) Licensor agrees to deliver to CREATIVE * copies of a combination of WebPhone and Video WebPhone, in a proportionate amount of each product to be determined solely be CREATIVE, within five (5) business days after the Amendment Effective Date; and (ii) CREATIVE agrees to place all future orders for WebPhone and Video WebPhone in combined quantities of * copies. The parties hereto acknowledge and agree that as of the Amendment Effective Date, CREATIVE has purchased a fully paid for a total of * copies pursuant to the terms of the Master Agreement and a total of * as of the Amendment Effective Date.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
MINIMUM SALES OBLIGATIONS. 3.1 Distributor shall be obligated to purchase from CTT that number of Product(s) during each Contract Year as is set forth in Schedule 2 hereto (for each such Contract Year, the "Product Minimums"). The Product Minimums for each of the first three (3) Contract Years are set forth in Schedule 2 hereto. The Product Minimums for Contract Year 3 and beyond shall be set by CTT in good faith taking into account the number of sales and the Quarterly Product Minimums (on both a quarterly and annual basis) for the prior Contract Year and shall be provided to Distributor at least ninety (90) days prior to the beginning of such new Contract Year. 3.2 The first Contract Year will start after this Agreement is signed and at the expiration of the XX day ramp up period following the effective date of the Agreement. Following this event, the "Selling Clock Starts Ticking" for the minimums required in the Contract Years. Immediately after this Agreement is signed within XX days and after the import license approval is released to the Distributor from the concerned authorities the Distributor will pre-pay for XX units from CTT at XX (USD) per unit. The Distributor shall submit to CTT for approval a XX years comprehensive business plan within XX months from the effective date of the Agreement, which will then indicate the targeted sales for Year 1, 2, 3, 4, 5. The Distributor shall anyway agree to purchase XX devices within 12 months from the approval to import and sell in the concerned territories and XX devices within the end of Year 3 from that approval to import and sell. All the details will be displayed in the business plan.
Sample 1
MINIMUM SALES OBLIGATIONS. STRAKAN shall adhere to the following minimum unit volume sales obligations if there is PATENT protection and/or MARKET EXCLUSIVITY position on the PRODUCT in the TERRITORY: *Year 1 50,000 5gm tubes Year 2 93,000 5gm tubes Year 3 134,000 5gm tubes Year 4 157,000 5gm tubes Year 5 180,000 5gm tubes Years 6-10 180,000 5gm tubes per year
Sample 1
MINIMUM SALES OBLIGATIONS. 3.1 Distributor shall be obligated to purchase from CTT that number of Product(s) during each Contract Year as is set forth in Schedule 2 hereto (for each such Contract Year, the "Product Minimums"). The Yearly Product Minimums for each Contract Year are set forth in Schedule 2 hereto. The Yearly Product Minimums beyond Contract Year 2 shall be set by CTT at [Confidential] annual growth from Contract Year 2 as set forth in Schedule 2. The start of the first Contract Year is defined in Section 3.2 3.2 The first Contract Year will start; (a) after this Agreement is signed, (b) treatment protocols and training are provided to ELS by CTT, and (c) at the expiration of a four month ramp up period following the effective date of the Agreement. Following these events, the "Selling Clock Starts Ticking" for the minimums required in the Contract Years. Immediately after this Agreement is signed by both parties and Indian regulatory approval has been received, CTT will provide ELS one unit at [Confidential] and ELS will purchase one unit from CTT at [Confidential] (USD). ELS will purchase 14 additional units, sent to ELS in three or less shipments, at [Confidential] per unit within [Confidential] days of when the "Selling Clock Starts Ticking" or upon receiving Indian regulatory approval, whichever is earlier The 15 purchased units will be counted towards the minimums required in the first Contract Year.
Sample 1
MINIMUM SALES OBLIGATIONS 
Sample 1

Related to MINIMUM SALES OBLIGATIONS

  • Minimum Royalties If royalties paid to Licensor do not reach the minimum royalty amounts stated in Section 3.3 of the Patent & Technology License Agreement for the specified periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid to Licensor.

  • Minimum Royalty At the beginning of each calendar year during the term of this Agreement, beginning January 1, 2016, Company shall pay to Medical School a minimum royalty of {***}. If the actual royalty payments to Medical School in any calendar year are less than the minimum royalty payment required for that year, Company shall have the right to pay Medical School the difference between the actual royalty payment and the minimum royalty payment in full satisfaction of its obligations under this Section, provided such minimum payment is made to Medical School within sixty (60) days after the conclusion of the calendar year. Waiver of any minimum royalty payment by Medical School shall not be construed as a waiver of any subsequent minimum royalty payment. If Company fails to make any minimum royalty payment within the sixty-day period, such failure shall constitute a material breach of its obligations under this Agreement, and Medical School shall have the right to terminate this Agreement in accordance with Section 8.3.

  • Minimum Annual Royalties Company shall pay to JHU minimum annual royalties as set forth in Exhibit A. These minimum annual royalties shall be due, without invoice from JHU, within thirty (30) days of each anniversary of the EFFECTIVE DATE beginning with the first anniversary. Running royalties and sublicense consideration accrued under Paragraphs 3.3 and 3.4, respectively, and paid to JHU during the one year period preceding an anniversary of the EFFECTIVE DATE shall be credited against the minimum annual royalties due on that anniversary date.

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Contract Quarterly Sales Reports The Contractor shall submit complete Quarterly Sales Reports to the Department’s Contract Manager within 30 calendar days after the close of each State fiscal quarter (the State’s fiscal quarters close on September 30, December 31, March 31, and June 30). Reports must be submitted in MS Excel using the DMS Quarterly Sales Report Format, which can be accessed at xxxxx://xxx.xxx.xxxxxxxxx.xxx/business_operations/ state_purchasing/vendor_resources/quarterly_sales_report_format. Initiation and submission of the most recent version of the Quarterly Sales Report posted on the DMS website is the responsibility of the Contractor without prompting or notification from the Department’s Contract Manager. If no orders are received during the quarter, the Contractor must email the DMS Contract Manager confirming there was no activity.

  • Minimum Annual Royalty Beginning in the calendar year after the first occurrence of SALEs, and in each succeeding calendar year thereafter, LICENSEE will pay to REGENTS a minimum annual royalty of [Written amount] U.S. Dollars ($ Number) for the life of this AGREEMENT. This minimum annual royalty will be paid to REGENTS by February 28 of each year and will be credited against the earned royalty due and owing for the calendar year in which the minimum payment is made.

  • Conditions to Xxxxx’x Obligations The obligations of Xxxxx hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by Xxxxx of a due diligence review satisfactory to Xxxxx in its reasonable judgment, and to the continuing satisfaction (or waiver by Xxxxx in its sole discretion) of the following additional conditions:

  • Sales Milestones (a) As to each Therapeutic Product, SANOFI-AVENTIS shall pay MERRIMACK up to a total of Sixty Million Dollars (US$60,000,000) upon the first achievement of the following Net Sales milestones, on a Therapeutic Product-by-Therapeutic Product basis: (i) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (ii) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (iii) Total Worldwide Net Sales for Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (b) Each milestone payment set forth in Section 8.4(a) shall be payable by SANOFI-AVENTIS upon the achievement of the related milestone event by SANOFI-AVENTIS and its Affiliates or sublicensees, and SANOFI-AVENTIS shall provide notice to MERRIMACK promptly upon achievement of such milestone event. SANOFI-AVENTIS shall pay MERRIMACK each such milestone payment within [**] days of such achievement of the related milestone event. (c) For purposes of clarity, more than one of the Net Sales milestones set forth above may be earned in the same four (4) consecutive calendar quarter period with respect to a Therapeutic Product. For example, if total worldwide Net Sales with respect to a given Therapeutic Product have not achieved any of the lower sales milestone thresholds set forth in clause (i) or (ii) of Section 8.3(a) above in any previous four (4) consecutive calendar quarter period, but total worldwide Net Sales with respect to such Therapeutic Product exceed $[**] in a subsequent four (4) consecutive calendar quarter period, then all three milestone payments, totaling $60 Million, payable upon achievement of the sales milestone thresholds set forth in clause (i), (ii) and (iii) of Section 8.3(a) above shall become payable to MERRIMACK hereunder.

  • Minimum Revenue Borrower and its Subsidiaries shall have Revenue from sales, marketing or distribution of the Product and related services (for each respective measured period, the “Minimum Required Revenue”): (a) during the twenty-four month period beginning on January 1, 2015, of at least $45,000,000; (b) during the twenty-four month period beginning on January 1, 2016, of at least $80,000,000; (c) during the twenty-four month period beginning on January 1, 2017, of at least $110,000,000; and (d) during the twenty-four month period beginning on January 1, 2018, of at least $120,000,000; and (e) during the twenty-four month period beginning on January 1, 2019, of at least $120,000,000.

  • Earned Royalties In partial consideration of the License and subject to Sections 3.7 and 3.8, Company will pay to Penn: (i) a graduated royalty as set forth in the table below based upon worldwide annual Net Sales made by Company and its Affiliates (but not sublicensees) of any Designated Compound Sold for use in the Field of Use while covered in the country of Sale of expected use by a Valid Claim of the Assigned BMS Patents that is licensed to Company under the License (but no other Licensed Product): <$500 million [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$500 million but <$750 million [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$750 million but <$1 billion [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$1 billion [CONFIDENTIAL TREATMENT REQUESTED] /*/% [CONFIDENTIAL TREATMENT REQUESTED] /*/ PATENT LICENSE AGREEMENT (ii) a royalty of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of Net Sales made by Company and its Affiliates (but not sublicensees) for all Licensed Products that qualify as “Licensed Products” hereunder based on clause (b) of that definition and Sold while covered in the country of Sale of expected use by a Valid Claim of the Penn Existing Patents or Penn New Patents; provided that, notwithstanding any credits provided for in Section 3.7 but subject in all events to Section 3.8, royalties payable by Company for such Net Sales for such Licensed Products shall not be less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%). Only one royalty shall be due hereunder on the Sale of the same unit of Licensed Product. If a royalty accrues to a Sale of a Licensed Product under both clause (i) and (ii) above, then the higher rate of clause (i) shall apply. Only one royalty shall be due hereunder on the Sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of such Licensed Product infringes more than one Valid Claim of the Penn Patent Rights.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!